#外资研报

图片

无图片

正文

无正文

总体总结

暂无总结

文档

UBS-中国股票策略:A 股 2026 年一季度业绩回顾盈利增速明显回升且利润率改善 China Equity Strategy A-share Q126 earnings review:Earnings growth picked up notably, margins improved.pdf

预览

UBS-中国股票策略:A 股 2026 年一季度业绩回顾盈利增速明显回升且利润率改善 China Equity Strategy A-share Q126 earnings review:Earnings growth picked up notably, margins improved.pdf

UBS-中国人工智能:DeepSeek V4:强化模型效率并加速算力本地化 China AI Intelligence DeepSeek V4:strengthening model efficiency and accelerating compute localisation.pdf

预览

UBS-中国人工智能:DeepSeek V4:强化模型效率并加速算力本地化 China AI Intelligence DeepSeek V4:strengthening model efficiency and accelerating compute localisation.pdf

UBS-中国软件与 IT 服务:短期盈利韧性较强,长期定位仍存不确定性 China Software and IT Services Near-term earnings strength;uncertain long term positioning.pdf

预览

UBS-中国软件与 IT 服务:短期盈利韧性较强,长期定位仍存不确定性 China Software and IT Services Near-term earnings strength;uncertain long term positioning.pdf

UBS-中国医疗:每周回顾:CSCO 新指南;2026 年一季度业绩汇总 China Healthcare Weekly recap CSCO new guidelines; Q126 results roundup.pdf

UBS-中微公司-688012-毛利率好于预期-20260428.pdf

预览

UBS-中微公司-688012-毛利率好于预期-20260428.pdf

UBS-韵达股份-002120-从价格战之痛到政策引领的盈利复苏-20260428.pdf

预览

UBS-韵达股份-002120-从价格战之痛到政策引领的盈利复苏-20260428.pdf

UBS-中国 CRO 行业:2026 年一季度后展望 —— 小分子 CDMO 需求强劲势头会延伸至生物药领域吗? China CRO Sector Post Q126 roadmap - will strength in small-molecule CDMO demand broaden to biologics.pdf

预览

UBS-中国 CRO 行业:2026 年一季度后展望 —— 小分子 CDMO 需求强劲势头会延伸至生物药领域吗? China CRO Sector Post Q126 roadmap - will strength in small-molecule CDMO demand broaden to biologics.pdf

UBS-中国房地产:深圳政策放松对贝壳(BEKE)构成利好 China Property Shenzhen policy easing; Positive for BEKE.pdf

预览

UBS-中国房地产:深圳政策放松对贝壳(BEKE)构成利好 China Property Shenzhen policy easing; Positive for BEKE.pdf

UBS-中国房地产:是复苏信号还是虚假曙光? China Property Signs of recovery or a false dawn.pdf